NICE makes u-turn decision on Lucentis

A UK health watchdog has recommended the use of Lucentis for the treatment of visual impairment caused by diabetic macular oedema (DMO) after manufacturer Novartis dropped the price of the drug.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news